| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.16 | 9e-06 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.0008 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |